BioCareSD, a specialty distributor of life-saving therapies, is proud to announce the addition of LEQEMBI to their diverse portfolio of specialty therapeutics. LEQEMBI was recently approved by the U.S. Food and Drug Administration (FDA) under the Accelerated Approval Pathway for the treatment of moderate-to-severe Alzheimer’s disease. The innovative new therapy developed by Biogen and Eisai has shown in studies that it may slow cognitive decline in early-stage Alzheimer’s disease. With this recent acquisition, BioCareSD hopes to expand the reach of this groundbreaking therapy for those suffering from this devastating condition.